PDF(Pubmed)
Abstract：
Glioma is a primary malignant tumor in the central nervous system. In recent years, the treatment of glioma has developed rapidly, but the overall survival of glioma patients has not significantly improved. Due to the presence of the blood-brain barrier and intracranial tumor barrier, many drugs with good effects to cure glioma in vitro cannot be accurately transported to the corresponding lesions. In order to enable anti-tumor drugs to overcome the barriers and target glioma, nanodrug delivery systems have emerged recently. It is gratifying that liposomes, as a multifunctional nanodrug delivery carrier, which can be compatible with hydrophilic and hydrophobic drugs, easily functionalized by various targeted ligands, biodegradable, and hypoimmunogenic in vivo, has become a quality choice to solve the intractable problem of glioma medication. Therefore, we focused on the liposome nanodrug delivery system, and summarized its current research progress in glioma. Hopefully, this review may provide new ideas for the research and development of liposome-based nanomaterials for the clinical treatment of glioma.
摘要：
胶质瘤是中枢神经体系的原发性恶性肿瘤。近年来,神经胶质瘤的治疗发展迅速，但胶质瘤患者的总体生存率并没有明显改善。由于血脑屏障和颅内肿瘤屏障的存在，许多在体外治疗胶质瘤效果良好的药物不能准确转运到相应的病灶。为了使抗肿瘤药物克服障碍,靶向胶质瘤,纳米药物递送系统最近出现。令人欣慰的是，脂质体，作为一种多功能的纳米药物载体，可以与亲水和疏水药物相容，容易被各种靶向配体官能化，可生物降解，体内免疫原性低，已成为解决神经胶质瘤用药棘手问题的质量选择。因此,我们专注于脂质体纳米药物递送系统，并对其目前在胶质瘤中的研究进展进行了综述。希望,本综述可能为临床治疗胶质瘤的脂质体纳米材料的研发提供新的思路。
